The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions

Breast Cancer Research and Treatment

Volumn 136, Issue 3, 2012, Pages 627-633

  Coopey, Suzanne B ^a   Mazzola, Emanuele ^b   Buckley, Julliette M ^a   Sharko, John ^a   Belli, Ahmet K ^a   Kim, Elizabeth M H ^c   Polubriaginof, Fernanda ^a   Parmigiani, Giovanni ^b,d   Garber, Judy E ^b   Smith, Barbara L ^a   Gadd, Michele A ^a   Specht, Michelle C ^a   Guidi, Anthony J ^e   Roche, Constance A ^a   Hughes, Kevin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NEWTON WELLESLEY HOSPITAL   (United States)

Author keywords

Atypical hyperplasia; Breast cancer; Chemoprevention; Lobular carcinoma in situ

Indexed keywords

EXEMESTANE; RALOXIFENE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ATYPICAL BREAST LESION; ATYPICAL DUCTAL HYPERPLASIA; ATYPICAL LOBULAR HYPERPLASIA; BREAST CANCER; BREAST LESION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UNITED STATES; ARTICLE; BREAST TUMOR; HYPERPLASIA; LUNG CARCINOMA; MAMMARY GLAND; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PRECANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOPREVENTION; FEMALE; HUMANS; HYPERPLASIA; MAMMARY GLANDS, HUMAN; MIDDLE AGED; PRECANCEROUS CONDITIONS; RALOXIFENE; TAMOXIFEN;

EID: 84878761849     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2318-8     Document Type: Review

References (31)

1. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146-151
2. Hartmann LC, Sellers TA, Frost MH, et al. (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229-237
3. Degnim AC, Visscher DW, Berman HK, et al. (2007) Stratification of breast cancer risk in women with atypia: a Mayo Cohort Study. J Clin Oncol 25(19):2671-2677
4. Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 55(11):2698-2708
5. Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2007) Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia. Results from the Nurses' Health Study. Cancer 109(2):180-187
6. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA (1997) Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 6:297-301
7. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S (2011) The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 137(7):1053-1060
8. Rosen PP, Lieberman PH, Braun DW, Kosloff C, Adair F (1978) Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 2(3):225-251
9. Haagensen CD, Lane N, Lattes R, Bodian C (1978) Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42:737-769
10. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22(12):1232-1239
11. Zurrida S, Bartoli C, Galimberti V, Raselli R, Barletta L (1996) Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ. Ann Surg Oncol 3(1):57-61
12. Bodian CA, Perzin KH, Lattes R (1996) Lobular neoplasia: long term risk of breast cancer and relation to other factors. Cancer 78(5):1024-1034
13. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS (1997) Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225(1):69-75
14. Wärnberg F, Yuen J, Holmberg L (2000) Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355:724-725
15. Franceschi S, Levi F, LaVecchia C, Randimbison L, Te VC (1998) Second cancers following in situ carcinoma of the breast. Int J Cancer 77:392-395
16. Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
17. Cummings SR, Eckert S, Krueger KA, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281(23):2189-2197
18. Vogel VG, Costantino JP, Wickerham DL, et al. (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 3(6):696-706
19. Goss PE, Ingle JN, Alés-Martínez JE, et al. (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381-2391
20. Ropka ME, Keim J, Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28(18):3090-3095
21. Buckley JM, Coopey SB, Mazzola E, et al. (2012) The feasibility of using natural language processing to extract clinical information from 76,000 breast pathology reports. J Pathol Inform 3:23-29
22. Page DL, Anderson TJ (1987) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh, pp 137-184
23. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41-55
24. Rubin DB (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763
25. Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5(3):299-314
26. Boughey JC, Hartmann LC, Anderson SS, et al. (2010) Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol 28(22):3591-3596
27. McLaren BK, Schuyler PA, Sanders ME, et al. (2006) Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer 107(6):1227-1233
28. Chuba PJ, Hamre MR, Yap J, et al. (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23(24):5534-5541
29. Cuzick J, DeCensi A, Arun B, et al. (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12:496-503
30. Fagerlin A, Zikmund-Fisher BJ, Smith DM, et al. (2010) Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119:613-620
31. Pankratz VS, Hartmann LC, Degnim AC, et al. (2008) Assessment of the accuracy of the gail model in women with atypical hyperplasia. J Clin Oncol 26(33):5374-5379